|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 22, 2002; DOI 10.1182/blood-2002-06-1704.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of Hematology and Center for
Nuclear Magnetic Resonance, Aarhus University Hospital, Aarhus,
Denmark.
The role of iron overload as cause of liver dysfunction has never
been studied in detail in patients without concomitant hepatotropic infections who receive multiple transfusions. We therefore investigated the relationship between the extent of hepatocellular injury as reflected by serum levels of aminotransferases (alanine
aminotransferase [ALT] and aspartate aminotransferase [AST]) and
several iron status indices in 39 anti-hepatitis C virus-negative
(HCV Liver disease associated with blood transfusion is
caused by hepatotropic infections or hepatic siderosis.1
Both factors may act either synergistically or independently in
promoting chronic liver disease, inducing cellular damage through
similar oxidative pathways.1 Even after the introduction
of hepatitis C virus (HCV) screening of blood prior to transfusion,
primary HCV infection is still the main cause of hepatotropic
infections, and thus an important cause of morbidity among patients
with HCV infection is an uncommon cause of liver dysfunction in multiply
transfused patients in Denmark where HCV prevalence is low.6 This afforded us a unique opportunity to study the
relationship between transfusional iron overload and liver disease
without coexisting liver disease caused by hepatotropic virus
infection. Remarkably few studies have focused on this issue in
nonthalassemic patients. Some studies have explored liver dysfunction
after bone marrow transplantation for hematologic
malignancies,7-11 but transfusional iron overload as the
sole cause of liver dysfunction is seen only in a minor fraction of
these patients.11 One small study examined liver
dysfunction in 15 adults with transfusional iron overload caused by
refractory anemias.12 Serologic tests for hepatitis B
virus infection were negative, but this study was also conducted before
the discovery of HCV.
It is now generally accepted that primary as well as secondary iron
overload can have prefibrogenic effects on the liver by giving rise to
a sustained condition of oxidative stress.13 Although
hepatic iron excess is characterized by a low degree of inflammation
and hepatocellular necrosis, this low necrogenic activity may initiate
and promote progressive fibrosclerosis, eventually leading to
cirrhosis.13 The relationship between the magnitude of
iron overload and the degree of hepatocellular injury has never been
studied in detail for the reasons mentioned above. Hence, it remains
unknown if hepatocellular injury depends on liver iron concentration,
as is the case in patients with hereditary hemochromatosis, who do not
seem to develop liver fibrosis or cirrhosis at liver iron concentration
levels below a certain critical threshold.14
This study seeks to fill this knowledge gap by investigating the
relationship between the extent of hepatocellular injury reflected in
the aminotransferase serum activities and the magnitude of
transfusional iron overload as assessed by several indices of body iron
status (liver iron concentration, serum ferritin, urinary iron
excretion, serum iron saturation of transferrin) in adult
nonthalassemic, anti-HCV Patients
All patients were tested for viral hepatitis B and C infection (see
"Serologic tests"). One patient had HCV antibodies and another
patient had biopsy-verified alcoholic liver disease before developing
transfusional iron overload. Both patients were excluded from the
study, leaving 39 eligible patients. All patients (14 women, 25 men)
had regular blood transfusions. All but 3 patients had exclusively
received erythrocyte suspensions screened for anti-HCV, hepatitis B
surface antigen (HBsAg), and anti-HIV-1 and -2. None had received iron
chelation treatment before entry into the study and none had had
venesections. Twenty-seven of the patients had a confirmed diagnosis of
myelodysplastic syndrome (MDS) of various stages. Three patients had
aplastic anemia, 1 had red cell aplasia, 4 had acute myeloid leukemia
in complete remission after autologous bone marrow transplantation, and
1 each had chronic hemolysis, chronic myeloid leukemia, chronic lymphatic leukemia, and myelofibrosis. Thirty-seven of 39 patients were
investigated for the Cys282Tyr mutation and the His63Asp variant within the HFE gene causing hereditary
hemochromatosis. We did not find patients who were homozygous for the
Cys282Tyr mutation or compound-heterozygous for the Cys282Tyr mutation
and the His63Asp variant, excluding cases of hereditary hemochromatosis caused by mutation within the HFE gene, but not excluding
rare cases caused by other known or still unknown mutations. We did, however, observe 5 patients heterozygous for His63Asp and 2 for Cys282Tyr.
Twelve anti-HCV Serologic tests All patients were tested for anti-HCV antibodies using a microparticle enzyme immunoassay (MEIA), detecting antibodies to HCV-encoded antigens recombinant HCr43, c200, c100-3, and NS5 (AxSYM HCV version 3.0, from Abbott Laboratories, Wiesbaden, Germany). All patients were tested for viral hepatitis B infection with an MEIA for HBsAg (AxSYM HBsAg [V2]), hepatitis B surface antibody (HbsAb; AxSYM AUSB), HBcAb (AxSYM Core and AxSYM Core-M) all from Abbott Laboratories.Investigations for the Cys282Tyr mutation and the His63Asp variant within the HFE gene were performed by polymerase chain reaction (PCR)-based restriction fragment length analysis (RFLA).18 The serum ferritin concentration was assessed by enzyme-immunometric assay (Amerlite, Ferritin assay, monoclonal; Amersham, Cardiff, United Kingdom). The reference range was 10 to 120 µg/L for women and 15 to 300 µg/L for men. The serum transferrin (Tf) concentration (reference range, 23-40 µM/L) was determined by nephelometric measurement of immune complexes using rabbit antibodies against human Tf. The serum iron concentration (reference range, 11-31 µM/L) was measured by a spectrophotometric method. Liver dysfunction was evaluated by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using a standard autoanalyzer-based method. The upper normal limits for both enzymes were 40 U/L. Iron chelation therapy DFO was administered subcutaneously in the abdominal wall by 12-hour infusions, 5 days a week with a computer-assisted infusion pump (CADD II; SIMS Deltec, St Paul, MN) in 5 patients and in 7 patients by twice daily subcutaneous bolus injections according to Jensen et al.17 The daily DFO dose was 2 g daily (2.5 g daily in patient 1). Vitamin C supplementation (200 mg once a day) was started 6 to 18 months after start of DFO therapy.Urinary iron excretion Iron excretion was determined by atomic absorption spectrophotometry19 based on 24-hour collections. Follow-up values represent means of three 24-hour collections, performed on successive days. In patients 3 and 12 urine samples were not available.Estimation of liver iron MRI studies were performed using a Philips Gyroscan (Best, The Netherlands), S 15-HP, operating at 1.5 T. The images were obtained using the following electrocardiographic-gated spin echo sequence: echo time = 25 ms, repetition time equal to the heart rate (500-960 ms). The field of view was 450 mm2 matrix = 256 × 256 pixels. Oblique images (15-25 slices, with a slice thickness of 9 mm) were recorded, visualizing the right liver lobe and posterior vertebral muscles in the same slice. The signal intensity (SI) for hepatic tissue and the posterior vertebral muscle were determined by use of operator-defined regions of interest, which were always more than 50 pixels. We then calculated the liver-to-muscle SI ratio and corrected for variable values of the repetition time as previously described.20 The MRI system was calibrated daily by testing the system resonance frequency and the signal-to-noise ratio using a performance phantom. Validation experiments20 have shown a close linear inverse and semilogarithmic relationship (R2 = 0.98; P < .0001) between the liver-to-muscle SI ratio and the liver iron concentration by chemical analysis of liver biopsies within the range of 5 to 650 µM Fe/g (dry weight). This method established a reference range for the liver iron concentration of 1 to 15 (mean ± 2 SD) µM/g. The day-to-day variation was 2.9 ± 2.7 µM/g (healthy controls).Data analysis Data are given as percentages or as means ± SD for continuous variables with symmetric distributions if not otherwise indicated. Data with skewed distributions are given as median. Linear relationships between variables were investigated by linear regression analysis (least square method). If appropriate, logarithmic transformation of the data was performed before analysis. The model quality was assessed by calculation of R2.Relationships between variables monitored during iron chelation (including repeated measurements on the same individual) were investigated by a locally weighted scatter plot smoother (lowess), producing lowess curves based on least squares fits. All statistical tests were 2-tailed. A significance level of P < .05 was used. All statistics were done by using Stat View 5.0 software for Macintosh (1992-1998 SAS Institute, Cary, NC).
Aminotransferase activities and iron status prior to iron chelation We found elevated ALT activity in 21 (54%) of 39 patients and elevated AST activity in 11 (28%) of 39 patients, which suggests increased hepatocellular cell injury induced by transfused iron. Serum ALT activity was generally higher than serum AST activity. Aminotransferase levels appeared dependent on liver iron concentration (Figure 1). Elevated ALT and AST values were seen only at liver iron concentrations above 300 µM/g and 400 µM/g, respectively. An elevated ALT was, however, only found in 21 (75%) of 28 patients and an elevated AST in 11 (39%) of 28 patients with these high liver iron levels. Elevated aminotransferase levels were not seen until the iron saturation was more than 75%. Twenty-one (68%) of 31 patients exceeding this saturation had elevated ALT and 11 of 31 patients (36%) had elevated AST. The logarithmically expressed serum ferritin concentration showed a close positive and linear relationship with the logarithmically expressed ALT serum activity (R2 = 0.55; P < .0001), and all patients with serum ferritin levels more than 2500 µg/L had elevated ALT values. The relationship between the logarithmically expressed serum ferritin and the logarithmically expressed AST serum activity was even closer (R2 = 0.62; P < .0001). We found no correlation between the number of blood units given and the aminotransferase serum activities.
Urinary iron excretion at start of iron chelation Twelve patients underwent treatment with DFO. All patients had a liver iron concentration exceeding 400 µM/g (range, 403-623 µM/g) at start of treatment (Table 1), except patient 9 who had been on iron chelation for 9 months on entering the study. Serum ferritin levels ranged from 1280 to 8715 µg/L, indicating heavy iron overload. In 10 of the 12 patients we measured the urinary iron excretion at start of treatment after administration of 2 g DFO given as continuous, subcutaneous 12-hour infusion by pump. The log-transformed urinary iron excretion rose steeply with the liver iron concentration between 400 and 600 µM/g, and was concomitantly closely, positively correlated with the log-transformed ALT activity (R2 = 0.64, P = .006) and with the AST activity (R2 = 0.57, P = .01). The log-transformed urinary iron excretion also correlated positively with the log-transformed serum ferritin concentration, but at a lower level of significance (R2 = 0.50, P = .02), and with the iron saturation of transferrin for saturations more than 75% (R2 = 0.64, P = .005). However, iron saturation was not significantly related to the ALT activity (R2 = 0.38, P = .05).Aminotransferase activities during DFO treatment Eight of the 12 patients had elevated ALT at start of treatment. Follow-up data (Figure 2A) show that the ALT activity and the serum ferritin concentration fell progressively and to the same degree during treatment (Figure 2A,B). ALT had reached normal levels after 12 months in all but 2 patients (nos. 1 and 6), and the serum ferritin had fallen below 4000 µg/L in all except patient 1. The 2 patients who had not obtained normal ALT levels had the largest blood transfusion requirement, and patient 1 also had the largest urinary iron excretion (Figure 2D). Whereas the ferritin curves suggest effective iron chelation in all other patients, the repeated follow-up of the liver iron concentration by MRI revealed conflicting results. Thus, treatment had induced highly effective iron depletion in only 7 of the 12 patients (high responders). In the other patients (low responders), the liver iron concentration decreased slowly in 3 patients (nos. 3, 4, and 8) and remained largely unchanged in 2 patients (nos. 1 and 6). These 2 had the highest transfusion requirements of all patients in the follow-up period. In high responders the liver iron concentration was below 200 µM/g after 21 months of iron chelation, whereas low responders still had liver iron concentrations exceeding 400 µM/g, except for one patient.
Aminotransferase activities and iron status during iron chelation The log-transformed aminotransferase activity levels were similarly related to the liver iron concentration prior to and during treatment (Figure 3A,B). Thus, elevated ALT or AST was only observed if liver iron concentration exceeded 350 µM/g. As was the case before treatment, not all patients exceeding the threshold had elevated aminotransferase activity. Fifty-five liver iron values were more than 350 µM/g, but only 26 (44%) corresponding ALT values and only 13 (24%) corresponding AST values were elevated. This finding suggests that other factors may affect the degree of hepatocellular injury. We therefore investigated whether the degree of hepatocellular injury could be related to the urinary iron excretion, which reflects the amount of chelatable iron, including non-transferrin-bound iron (NTBI), a component of plasma iron assumed to be potentially toxic.21 Figure 4A shows a plot of the log-transformed ALT activity by the log-transformed urinary iron excretion. The lowess curve suggests that the ALT activity is not related to the urinary iron excretion below an iron excretion of around 10 mg/24 h. But at higher iron excretions we observed a proportional increase in log-transformed ALT with the log-transformed urinary iron excretion, which was similar to the findings at start of treatment. The urinary iron excretion also depended on the liver iron concentration, because it increased in proportion to liver iron concentration at values above approximately 400 µM/g (Figure 4C). Moreover, all elevated ALT values were associated with a urinary iron excretion of at least 15 mg/24 h (Figure 4C). The plot of the serum ferritin concentration to the liver iron concentration (Figure 4D) also showed an increase in the slope of the regression curve for liver iron concentrations more than 400 µM/g, but it was moderate compared with the rise in urinary iron excretion and the variation was larger. The findings suggest that urinary iron is more directly related to the liver iron concentration than to the serum ferritin concentration, as long as the liver iron concentration exceeds 350 µMl/g. Similar to the findings at the start of treatment, the serum ferritin values (> 1000 µg/L) were closely related to the log-transformed ALT activity (Figure 4B) and to the AST activity.
To our knowledge, this is the first study describing the relationship between liver function and liver iron concentration in patients with transfusional iron overload without serologic evidence of coexisting infection with major hepatotropic viruses excluding factors able to contribute to the extent of hepatocellular injury induced by iron. Causes of hepatocellular injury other than transfusional iron overload cannot, however, be excluded. Thus, patterns of ALT serum levels commonly seen in posttransfusion hepatitis in thalassemic patients have been demonstrated in patients without known hepatotropic infection.22 Alcohol ingestion is another well-known cause of elevated aminotransferase activity, and we excluded one patient from the study due to alcoholic liver disease. In none of the other patients was alcohol abuse suspected. Our investigations show that aminotransferase serum activity in patients with transfusional iron overload caused by acquired anemias depends on the liver iron concentration and is directly related to the log-transformed urinary iron excretion. We observed increased prechelation hepatocellular injury reflected in elevated aminotransferase activities only when liver iron concentrations exceeded 300 to 400 µM/g. During iron chelation the aminotransferase activities became normal when levels fell below 350 µM/g. These observations strongly suggest the existence of a critical liver iron concentration level or range of 300 to 400 µM/g that determines whether transfusional iron deposited within the liver induces hepatocellular injury or not. A critical liver iron concentration for hepatocellular injury is consistent with the critical liver iron concentration of 400 µM/g for development of hepatic fibrosis in hereditary hemochromatosis as suggested by Basset et al,14 and, indeed this concentration is close to the critical level reported here. We assessed the extent of hepatocellular injury by determining the aminotransferase serum activity, which is mainly caused by leakage of the enzymes from cytoplasmic and mitochondrial compartments of injured hepatocytes to the plasma.23 A normal aminotransferase activity, however, does not necessarily ensure absence of developing tissue damage caused by fibrogenesis because the fibrogenic process induced by iron is associated with little cell damage and inflammation, often with borderline or even normal transaminase levels.13 Iron may induce fibrogenesis without pre-existing hepatocellular injury.24 A recent study in patients with hereditary hemochromatosis showed that only 77% of the homozygous patients with severe fibrosis or cirrhosis had elevated aminotransferase levels.25 Unfortunately, we did not have the possibility of studying liver histology in our patients because many were pancytopenic, increasing the risk of side effects of liver biopsy. Fibrogenesis caused by pre-existing hepatocellular injury may, however, be identified by elevated aminotransferase levels. Measurements of urinary iron excretion at the start of treatment
clearly showed that the extent of hepatocellular injury was most
closely related to urinary iron excretion, but also significantly related to serum ferritin concentration. The corresponding follow-up data during iron chelation showed a similar pattern. The close relationship between the ALT activity and serum ferritin probably reflects a parallel leakage of aminotransferase and ferritin from the
injured cells to the plasma in addition to an increased ferritin synthesis. A significant, positive correlation between aminotransferase serum activities and the serum ferritin concentration was also shown in
an earlier study on The close correlation between aminotransferase activity and urinary iron excretion demonstrated at start of treatment and the finding of a comparable pattern during iron chelation suggests that the extent of hepatocellular injury is mainly determined by the size of the chelatable iron pool, as reflected by the urinary iron excreted. The observation that ALT was elevated only when the critical liver iron concentration was exceeded and the urinary iron excretion was above approximately 15 mg/24 h suggests that the chelatable iron pool only expands beyond the critical size when the liver iron concentration exceeds a critical concentration. The cytosolic, labile iron pool (LIP), classically referred to as the chelatable iron pool, contains the metabolically active forms of intracellular iron.28 The pool also contains forms of iron loosely associated with macromolecular complexes and possibly also the low-molecular-weight non-transferrin-bound plasma iron fraction (NTPI).29,30 Efficient regulatory mechanisms prevent fluctuations in LIP, but massive iron loading may result in uncontrollable expansion of the pool, which fails to be matched by the sequestrating capacity of cellular ferritin.31 The critical liver iron concentration, as suggested by our data, may reflect a critical iron load within the hepatocyte that exceeds the iron sequestrating capacity of the mentioned regulatory system. A liver iron concentration exceeding the critical level may therefore allow the chelatable iron pool to expand uncontrollably proportional to further hepatic iron accumulation. This may cause a proportional increase in hepatocellular injury and leakage of aminotransferase enzymes and ferritin to the plasma. The observed normalization of the aminotransferase serum activity observed when the liver iron concentration drops below the critical level may, on the other hand, reflect a restoration of the regulatory system controlling the size of the chelatable iron pool. Other defense mechanisms may, however, also be at play such as a cellular protective system like the variety of antioxidant cellular defenses counteracting the effect of oxyradical production.32 The close relationship between serum ferritin concentration and ALT
activity demonstrated in our study has implications for the usefulness
of the serum ferritin concentration as a marker of effective iron
chelation therapy. Decreasing ferritin values may not reflect a
proportional decrease in the body iron store but rather reflect
improved liver function caused by a minor reduction of the liver iron
concentration just below the critical range for hepatocellular injury.
Despite this limitation, the ferritin test has been shown to reflect
clinical outcome in patients with In conclusion, hepatocellular injury as reflected by elevated aminotransferase serum activity induced by transfusional iron overload in adult patients with transfusional iron overload caused by acquired anemias, and without serologic evidence of infection with major hepatotropic viruses, is dependent on the liver iron concentration. Our data suggest the existence of a critical liver iron concentration range above which hepatocellular injury is seen. The extent of the hepatocellular injury seems mainly to be determined by the size of the chelatable iron pool, as evaluated by the urinary iron excretion. Our findings support the concept of LIP as the compartment directly involved in iron toxicity. The findings may be helpful in establishing criteria for safety from complications of transfusional siderosis.
Submitted June 11, 2002; accepted August 5, 2002.
Prepublished online as Blood First Edition Paper, August 22, 2002; DOI 10.1182/blood-2002-06-1704.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Peter D. Jensen, Department of Hematology, Aarhus University Hospital, Amtssygehus, Tage Hansensgade 2, DK-8000 Aarhus C, Denmark; e-mail: d222615{at}inet.uni2.dk.
1. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-768[CrossRef][Medline] [Order article via Infotrieve]. 2. Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox Sang. 2000;79:129-137[CrossRef][Medline] [Order article via Infotrieve]. 3. De Virgiliis S, Cornacchia G, Sanna G, et al. Chronic liver disease in transfusion-dependent thalassemia: liver iron quantitation and distribution. Acta Haematol. 1981;65:32-39[Medline] [Order article via Infotrieve]. 4. Hoffbrand AV, Gorman A, Laulicht M, et al. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet. 1979;1:947-949[Medline] [Order article via Infotrieve].
5.
Aldouri MA, Wonke B, Hoffbrand AV, et al.
Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
J Clin Pathol.
1987;40:1353-1359 6. Lund BV, Korsgaard N, Peterslund NA. Hepatitis C antibody in hematological patients who underwent multiple transfusions. Ugeskr Laeger. 1991;153:3084-3086[Medline] [Order article via Infotrieve]. 7. Azar N, Valla D, Abdel-Samad I, et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation. 1996;62:56-61[CrossRef][Medline] [Order article via Infotrieve]. 8. McKay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17:63-66[Medline] [Order article via Infotrieve]. 9. Strasser SI, Kowdley KV, Sale GE, McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant. 1998;22:167-173[CrossRef][Medline] [Order article via Infotrieve]. 10. Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia: manifestations and therapy. Am J Med Sci. 2000;319:73-78[CrossRef][Medline] [Order article via Infotrieve]. 11. Tomas JF, Pinilla I, Garcia-Buey ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant. 2000;26:649-655[CrossRef][Medline] [Order article via Infotrieve]. 12. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304:319-324[Abstract]. 13. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med. 2000;21:49-98[CrossRef][Medline] [Order article via Infotrieve]. 14. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6:24-29[Medline] [Order article via Infotrieve]. 15. Jensen PD, Jensen FT, Christensen T, et al. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. Magma. 2001;12:153-166[Medline] [Order article via Infotrieve]. 16. Jensen PD, Olsen N, Bagger JP, et al. Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload. Eur J Haematol. 1997;59:221-230[Medline] [Order article via Infotrieve]. 17. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br J Haematol. 1995;89:880-889[Medline] [Order article via Infotrieve]. 18. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 1997;349:321-323[CrossRef][Medline] [Order article via Infotrieve]. 19. Zettner A, Mansbach L. Application of atomic absorption spectrophotometry in the determination of iron in urine. Am J Clin Pathol. 1965;44:517-519[Medline] [Order article via Infotrieve]. 20. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol. 1994;87:171-184[Medline] [Order article via Infotrieve]. 21. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol. 1998;101:399-406[CrossRef][Medline] [Order article via Infotrieve].
22.
Prati D, Zanella A, Farma E, et al.
A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia.
Blood.
1998;92:3460-3464 23. Boyd JW. The intracellular distribution, latency and electrophoretic mobility of L-glutamic oxaloacetic transaminase. Biochem J. 1970;81:433-438. 24. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol. 1998;28(suppl 1):8-13[Medline] [Order article via Infotrieve]. 25. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281-289[CrossRef][Medline] [Order article via Infotrieve]. 26. Worwood M, Cragg SJ, Jacobs A, et al. Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol. 1980;46:409-416[Medline] [Order article via Infotrieve].
27.
Wonke B, Hoffbrand AV, Brown D, Dusheiko G.
Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.
J Clin Pathol.
1990;43:638-640
28.
Jacobs A.
Low molecular weight intracellular iron transport compounds.
Blood.
1977;50:433-439 29. Crichton RR, Ward RJ. Iron species in iron homeostasis and toxicity. Analyst. 1995;120:693-697[CrossRef][Medline] [Order article via Infotrieve].
30.
Breuer W, Epsztejn S, Cabantchik ZI.
Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II).
J Biol Chem.
1995;270:24209-24215 31. Breuer W, Epsztejn S, ZI C. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 1997;382:304-308. 32. Inoue M. Protective mechanisms against reactive oxygen species Arias IM, Bojer JL, Fausto N, Jacoby WB, Schachter D,. Shafritz DA, eds. The Liver. Biology and Pathobiology. New York, NY: Raven Press; 1994:443-459.
33.
Olivieri NF, Nathan DG, MacMillan JH, et al.
Survival in medically treated patients with homozygous beta-thalassemia.
N Engl J Med.
1994;331:574-578 34. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-977[CrossRef][Medline] [Order article via Infotrieve].
35.
Olivieri NF, Brittenham GM.
Iron-chelation therapy and the treatment of thalassemia.
Blood.
1997;89:739-761
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. Jabbour, G. Garcia-Manero, A. Taher, and H. M. Kantarjian Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy Oncologist, May 1, 2009; 14(5): 489 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rose, O. Ernst, B. Hecquet, P. Maboudou, P. Renom, M. P. Noel, I. Yakoub-Agha, F. Bauters, and J. P. Jouet Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long-term survivors after allogeneic hematopoietic stem cell transplantation Haematologica, June 1, 2007; 92(6): 850 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Le Lan, O. Loreal, T. Cohen, M. Ropert, H. Glickstein, F. Laine, M. Pouchard, Y. Deugnier, A. Le Treut, W. Breuer, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis Blood, June 1, 2005; 105(11): 4527 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Jensen, F. T. Jensen, T. Christensen, H. Eiskjaer, U. Baandrup, and J. L. Nielsen Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool Blood, June 1, 2003; 101(11): 4632 - 4639. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) nonthalassemic patients with transfusional iron
overload owing to acquired anemias. In 12 patients, we monitored
aminotransferase levels and indices of iron status during iron
chelation treatment. Before treatment, elevated aminotransferase
activity was seen only at liver iron concentrations more than 300 µM/g. During treatment all aminotransferase values were
normal if the liver iron concentration returned below 350 µM/g. At
the start of treatment, ALT
(R2 = 0.64, P = .006)
and AST activity (R2 = 0.57,
P = .01) were closely related to urinary iron excretion, reflecting the size of the chelatable or the labile iron pool. During
treatment, a comparable pattern was seen and the urinary iron excretion
was also directly related to the liver iron concentration at
concentrations above approximately 400 µM/g. All elevated ALT values
were associated with a urinary iron excretion more than 15 mg/24 h. In
conclusion, our data suggest the existence of a critical liver iron
concentration range, above which hepatocellular injury is seen. The
extent of the injury seems to be determined mainly by the size of the
chelatable or labile iron pool, supporting the concept of the labile
iron pool as the compartment directly involved in iron toxicity. Our
findings may be helpful in establishing criteria for safety from
complications of transfusional iron overload.
(Blood. 2003;101:91-96)
-thalassemia who receive multiple transfusions.
